Lotus Pharmaceutical Co., Ltd. Share Price Taipei Exchange
Equities
1795
TW0001795003
Pharmaceuticals
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
108 TWD | +0.47% | -4.42% | -.--% |
Sales 2024 * | 18.82B 579M 48.3B | Sales 2025 * | 21.2B 652M 54.41B | Capitalization | 87.01B 2.68B 223B |
---|---|---|---|---|---|
Net income 2024 * | 4.84B 149M 12.43B | Net income 2025 * | 6.2B 191M 15.91B | EV / Sales 2024 * | 4.93 x |
Net Debt 2024 * | 5.71B 176M 14.66B | Net Debt 2025 * | 1.56B 48.08M 4.01B | EV / Sales 2025 * | 4.18 x |
P/E ratio 2024 * |
17.8
x | P/E ratio 2025 * |
14.5
x | Employees | - |
Yield 2024 * |
1.63% | Yield 2025 * |
2.28% | Free-Float | 48.47% |
Latest transcript on Lotus Pharmaceutical Co., Ltd.
1 day | +0.47% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | - | 29/14/29 | |
I ling Tian
DFI | Director of Finance/CFO | - | 01/16/01 |
Ying Ming Yue
COO | Chief Operating Officer | - | 01/22/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Vilhelm Wessman
CHM | Chairman | 54 | 23/15/23 |
Director/Board Member | 60 | 11/14/11 | |
Director/Board Member | 61 | 23/15/23 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+26.47% | 661B | |
+26.74% | 566B | |
-6.33% | 352B | |
+19.35% | 332B | |
+4.23% | 283B | |
+13.43% | 231B | |
+4.71% | 200B | |
-9.53% | 195B | |
-4.04% | 145B |
- Stock Market
- Equities
- 1795 Stock
- 1795 Stock